Back to School: How biopharma can reboot drug development. Access exclusive analysis here

UnGluing safety concerns

Eli Lilly and Co. believes its first-in-clinic metabotropic glutamate receptor subtype 2/3 agonist, LY2140023, may address the safety concerns associated with marketed antipsychotics. The reason is the specificity for mGluR2/3 and no significant affinity for other glutamate receptor subtypes and transporters, or for nonglutamate receptors such as dopamine or serotonin.

Other glutamate receptors have been associated with toxicity,

Read the full 588 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers